CPS
  • Home

Sign in or register to track your progress, save, and view your completed history.

Breast Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head & Neck Cancer, Urothelial Cancer​

Evaluating PD-L1 Across a Range of Tumor Types using Combined Positive Score (CPS)

    clockimg 59m
  • Webinar
  • Intermediate
 saveimgSave unsaveimgUnsave

 

The Precision Pathology Insights webinar series brings you expert PD-L1 evaluation insights. Since 2017, the series has provided key perspectives from industry leaders to help sharpen your Combined Positive Score (CPS) expertise and PD-L1 evaluation skills. 

 

This webinar is presented by Ed Manna, CDx Pathology Manager at Agilent Technologies and moderated by Douglas P. Clark, MD, the Chief Pathologist at the CDx Division in Agilent Technologies. Recorded on 21 June 2023.​

 

In this webinar, veteran pathology trainer, Ed Manna, provides expert insight into CPS, including:  ​

  • Indication-specific observations and variations in scoring across different tumor types (e.g., HNSCC, TNBC, Cervical Cancer, and Esophageal Cancer)​
  • Inclusion and exclusion criteria when evaluating PD-L1–stained specimens with CPS​
  • Assessing CPS reproducibility across different tumor types​
  • Real-world scoring and case example walkthroughs​

Ed Manna, CT​

CDx Pathology Manager​, Agilent Technologies​

Douglas P. Clark, MD​

Chief Pathologist, CDx Division, Agilent Technologies

Related Training

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details.​D0113753_1.00